By Gabriel Paijo 
A landmark study conducted by a multidisciplinary team of Brazilian scientists has uncovered a critical molecular mechanism that allows pancreatic cancer to transition from a localized tumor to an invasive, metastatic disease at an unexpectedly early stage. Published in the prestigious journal Molecular and Cellular Endocrinology, the research identifies a specific protein, periostin, as a primary driver of perineural invasion—a process where cancer cells hijack the body’s nervous system to spread beyond the primary site. By mapping the complex interactions between malignant cells and the surrounding healthy tissue, the study provides a new roadmap for precision medicine and offers hope for developing therapies that could halt the progression of one of the world’s deadliest cancers.
The research, spearheaded by the Center for Research on Inflammatory Diseases (CRID) and supported by the São Paulo Research Foundation (FAPESP), reveals that pancreatic tumors do not exist in isolation. Instead, they act as master manipulators of their environment, effectively "reprogramming" nearby healthy cells to facilitate their own expansion. This discovery shifts the focus of oncology from looking solely at the cancer cells themselves to examining the entire "tumor microenvironment," particularly the role of pancreatic stellate cells and the structural proteins they secrete.
The Biological Mechanism of Early Invasion
At the heart of the study’s findings is the relationship between pancreatic cancer cells and stellate cells—specialized cells in the pancreas that, when activated, contribute to the formation of connective tissue. The researchers discovered that these stellate cells produce high concentrations of periostin, a protein that plays a pivotal role in remodeling the extracellular matrix (ECM). The ECM is the scaffolding that holds cells together in healthy tissue; however, in the presence of a tumor, periostin alters this structure, creating a pathway for cancer cells to break free.
This remodeling process is not a passive side effect of tumor growth but a coordinated invasion strategy. Specialized enzymes are deployed to break down the physical barriers of the pancreas, allowing cancer cells to infiltrate nearby nerve fibers. Once a cancer cell reaches a nerve, it gains access to a high-speed transit system. Because the nervous system is an interconnected network reaching throughout the body, this "perineural invasion" (PNI) allows the cancer to bypass traditional circulatory routes and establish metastatic colonies in distant organs.
According to Dr. Helder Nakaya, a senior researcher at Einstein Israelite Hospital and a professor at the University of São Paulo, the ability to map these interactions at a cellular level was made possible by advanced bioinformatics. "We utilized single-cell transcriptomics to analyze the activity of thousands of genes simultaneously," Nakaya explained. "This allowed us to see exactly which cells were producing periostin and how those cells were communicating with the tumor to facilitate the invasion of the nervous system."
Pancreatic Adenocarcinoma: A Global Health Crisis
The findings are particularly significant given the devastating nature of the disease. Pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90% of all pancreatic cancer cases. It is often referred to as a "silent killer" because it rarely presents symptoms in its early, more treatable stages. By the time a patient experiences jaundice, weight loss, or abdominal pain, the cancer has often already begun its invasive journey along the nerves.
The global statistics for pancreatic cancer are sobering. Approximately 510,000 new cases are diagnosed annually worldwide, and the mortality rate remains tragically close to the incidence rate. Unlike many other forms of cancer, such as breast or prostate cancer, where five-year survival rates have improved significantly over the last three decades, the survival rate for pancreatic cancer remains stuck in the low double digits.
In Brazil, the National Cancer Institute (INCA) estimates that the disease claims roughly 13,000 lives each year, out of 11,000 new diagnoses—a statistical anomaly that highlights how many cases are discovered too late for effective intervention. Dr. Pedro Luiz Serrano Uson Junior, an oncologist and co-author of the study, notes that only about 10% of patients achieve long-term survival. "The aggressiveness of this cancer is tied directly to its ability to infiltrate surrounding tissues and nerves before we even know it is there," Uson said.
The "Roadmap" of Perineural Invasion
Perineural invasion is a hallmark of aggressive pancreatic cancer, and the Brazilian study clarifies why this process is so difficult to stop. Unlike the lymphatic system or the bloodstream, which have various "checkpoints" such as lymph nodes, the nervous system provides a direct, unencumbered path for cancer cells.
When cancer cells invade a nerve, they don’t just move along it; they often cause significant nerve damage and inflammation, which translates into the severe, chronic pain frequently reported by pancreatic cancer patients. This pain is not just a symptom but a clinical marker of the tumor’s progression. The study shows that the presence of periostin-rich environments near nerves is a strong predictor of poor clinical outcomes.
Furthermore, the researchers noted that more than 50% of patients already exhibit signs of perineural invasion at the time of their initial diagnosis, even if the tumor appears localized on imaging. Currently, this invasion is usually only confirmed after a surgical biopsy, meaning that by the time doctors realize the cancer has spread along the nerves, the window for curative surgery may have already closed.
The Desmoplastic Barrier: Why Treatment Fails
One of the most frustrating challenges in treating pancreatic cancer is the "desmoplastic reaction." As the tumor grows and the stellate cells produce periostin and other proteins, the area around the tumor becomes encased in a dense, fibrous, and scar-like tissue. This creates a physical "armor" around the cancer.
This hardened microenvironment does more than just help the cancer spread; it actively protects it from medical intervention. The dense tissue increases the internal pressure of the tumor, collapsing small blood vessels and preventing chemotherapy and immunotherapy drugs from reaching the malignant cells. "This explains why even the most advanced drugs often fail in pancreatic cancer," Dr. Uson remarked. "The drug simply cannot penetrate the fortress that the tumor has built around itself."
By identifying periostin as a key architect of this "fortress," the research opens the door to therapies that could potentially "soften" the tumor. If the production of periostin can be inhibited, the desmoplastic reaction might be reduced, making the tumor more vulnerable to existing treatments.
Methodology and the Power of Data
The study’s success was rooted in its innovative use of data. The research team examined 24 high-quality pancreatic cancer samples, but they did not stop there. They integrated their findings with massive public databases, re-analyzing existing genomic data through the lens of their new hypothesis.
"The power of modern science lies in our ability to ask new questions of old data," said Nakaya. By using spatial transcriptomics, the team was able to see not just which genes were turned on, but where they were active in relation to the tumor and the nerves. This "spatial mapping" confirmed that periostin activity was highest at the exact points where the tumor met the stroma (the connective tissue) and the nervous system.
This approach allowed the researchers to bypass the limitations of traditional pathology, which often looks at a "snapshot" of a tumor without understanding the dynamic communication happening between different cell types.
Implications for the Future of Precision Medicine
The discovery of periostin’s role has immediate implications for the future of oncology. Clinical trials are already underway for other types of cancer—such as breast and lung cancer—testing antibodies that block periostin. The Brazilian team believes that these therapies could be repurposed for pancreatic cancer patients, potentially preventing the early spread that makes the disease so lethal.
The vision for the future is a shift toward "precision medicine," where treatment is determined by the molecular profile of a patient’s tumor rather than just its location in the body. If a biopsy reveals high levels of periostin and activated stellate cells, doctors could theoretically administer a "blocking" therapy alongside traditional chemotherapy.
"We are moving toward a world where we treat the molecular change, not just the organ," said Dr. Uson. "If we can develop drugs that target the stellate cells or the periostin they produce, we can stop the tumor from acquiring its invasive capacity. This would be a game-changer not only for pancreatic cancer but for other cancers that utilize similar pathways, such as colorectal and breast cancers."
Conclusion and Next Steps
The Brazilian study represents a significant leap forward in understanding the "hidden support system" that allows pancreatic cancer to be so resilient. By identifying periostin as a key vulnerability, the researchers at CRID, FAPESP, and USP have provided a tangible target for drug development.
The next phase of the research will involve laboratory testing of periostin inhibitors to see if they can effectively halt perineural invasion in animal models. While clinical application may still be years away, the clarity provided by this study offers a new strategy in a field that has seen few victories. For the hundreds of thousands of families affected by pancreatic cancer each year, the identification of this "invasive roadmap" is a vital step toward turning a once-unbeatable disease into a manageable one.
